---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-045729"
form_type: "8-K"
ticker: "CALC"
cik: "0001534133"
company_name: "CalciMedica, Inc."
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T03:52:52.056843+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# CalciMedica reports FY2024 net loss $13.7M; cash $18.7M, funding into mid-2026

## Summary
- Net loss $13.7M in 2024 (vs $34.4M in 2023); R&D $14.5M, G&A $9.7M.
- Cash $18.7M at Dec 31, 2024; plus $9.7M net from March 2025 debt facility; runway into mid-2026.
- Phase 2 KOURAGE trial in AKI enrolling; data expected around end of 2025.
- Post-hoc CARDEA analysis: 62.7% relative mortality reduction in AKI patients at day 30.
- End-of-Phase 2 FDA meeting for acute pancreatitis program planned for mid-2025.

## SEC filing metadata
- accession: 0000950170-25-045729
- form_type: 8-K
- ticker: CALC
- cik: 0001534133
- company_name: CalciMedica, Inc.
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534133/000095017025045729/0000950170-25-045729-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534133/000095017025045729/ck0001534133-20250327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-045729
- JSON: https://secwatch.observer/filing/0000950170-25-045729.json
- Plain text: https://secwatch.observer/filing/0000950170-25-045729.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.